RRML - Genotype-phenotype correlations in patients treated with acenocoumarol

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2020): 1.027

Rejection rate (2020): 75%

Română English

Clarivate analytics (ISI) Impact factor

Advanced search

Top 10 downloaded articles
- May 2022 -
Approaching Risk Management in... 16
Screening of a novel BRCA2 mut... 14
Romanian Review of Laboratory ... 9
Matrix-assisted Laser Desorpti... 9
Proposal of a prediction model... 9
The evaluation of a diagnostic... 8
The evaluation of the preanaly... 7
Associations of serum expressi... 7
Downregulation of hsa-miR-4328... 7
Clinical significance of serum... 6

Log in

Concept, Design & Programming
Dr. Adrian Man

Nr. 22(3)/2014 DOI:10.2478/rrlm-2014-0032

Genotype-phenotype correlations in patients treated with acenocoumarol

Florentina Claudia Militaru, Ștefan Cristian Vesa, Sorin Crișan, Valentin Militaru, Adrian Pavel Trifa, Anca Dana Buzoianu


Aim: This research aims to establish a genotype-phenotype correlation in patients treated with acenocoumarol and studies the genetic factors (VKORC1 and CYP2C9 polymorphisms) that may influence INR values during initiation of oral anticoagulant therapy with acenocoumarol. Material and methods: We included 131 patients that needed treatment with acenocoumarol, 70 (53.4%) women and 61 (46.6%) men, observed at the 5th Medical Clinic in Cluj-Napoca, between 2009-2011. We studied the influence of age, gender, concomitant medication and of CYP2C9 and VKORC1 genes on the INR value recorded on the third day of treatment and on the difference between this value and the initial INR value at the starting point for the treatment (INRDIF). Results and conclusion: We demonstrated a statistically significant difference for INR3 and INRDIF values in patients with AA genotype and those with GG genotype of the c.-1639G>A polymorphism of the VKORC1 gene. The presence of AA genotype of the c.-1639G>A polymorphism of the VKORC1 gene determined a 15.7-fold increase in the risk that a patient might display supratherapeutic INR after 2 days of treatment with 4 mg of acenocoumarol.

Keywords: Acenocoumarol, CYP2C9, INR, VKORC1

Received: 13.5.2014
Accepted: 10.8.2014
Published: 2.9.2014

  PDF Download full text PDF
(286 KB)
How to cite
Militaru FC, Vesa ȘC, Crișan S, Militaru V, Trifa AP, Buzoianu AD. Genotype-phenotype correlations in patients treated with acenocoumarol. Rev Romana Med Lab. 2014;22(3):347-54. DOI:10.2478/rrlm-2014-0032